Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors

Table 1 Breast cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)		@ 1st assessment
Gordon et al[50]	Therasphere	Breast (75)	RECIST and PET	RECIST	6.6 mo
(8/2014 Epub, RS)	(mean 1.52 Gbq)		@ 1.4 mo (median)	24 (35.3) PR
				43 (63.2) SD
				1 (1.5) PD
				7 lost
				PET
				3 (12) CR
				18 (72) PR or SD
				4 (16) PD
				50 lost
Seyal et al[48]	Unspecified	Breast (21)	RECIST 1.1	34 lesions	None
(8/2014, RS)	(no dosage info)	34 lesions	@ unspecified	6 (17.7) PR
				27 (79.4) SD
				1 (2.9) PD
Saxena et al[47]	SIR-Spheres	Breast (40)	RECIST	2 (5) CR	13.6 mo
(12/2013, RS)	(mean 1.67 Gbq)		@ 1 mo	10 (26) PR
				15 (39) SD
				11 (29) PD
				2 lost
Cianni et al[33]	SIR-Spheres	Breast (77)	RECIST and PET	29 (56) PR	11.5 mo
(1/2013, RS)	(median 1.9 Gbq)		@ 1.8 mo	18 (35) SD
				5 (10) PD
				25 ineligible
Jakobs et al[39]	SIR-Spheres	Breast (30)	RECIST	14 (61) PR	11.7 mo (all)
(5/2008, PC)	(mean 1.9 Gbq)		@ 4.2 mo (median)	8 (35) SD	23.6 mo (responders)
				1 (4) PD	5.7 mo (nonresponders)
				7 lost
Coldwell et al[35]	SIR-Spheres	Breast (44)	RECIST and PET	RECIST	Median OS not reached
(3/2007, RS)	(median 2.1 Gbq)		@ 2.8 mo	17 (47) PR
				17 (47) SD	86% 14-mo survival
				2 PD (5) PD
				8 lost
				PET scans
				42 (95) response
				2 (5) no response/progression
Bangash et al[31]	Therasphere	Breast (27)	WHO and PET	WHO	Median OS not given.
(5/2007, PC)	(median 1.70 Gbq, mean 2.05 Gbq)		@ 3 mo	9 (39.1) CR/PR	6.8 mo (ECOG 0)
				12 (52.1) SD	2.6 mo (ECOG 1,2,3)
				2 (8.8) PD 4 lost	9.4 mo (< 25% tumor burden)
				PET 17 (63) response	2.0 mo (> 25% tumor burden)
				10 (37) no response
Cianni et al[34]	SIR-Spheres	Breast (32, data extracted from larger study)	RECIST	14 (44) CR/PR	None
(1/2010, RS)	(mean 1.64 Gbq)		@ 1.8 mo	11 (34) SD
				7 (22) PD
Reiner et al[46]	SIR-Spheres	Breast (1, data extracted from larger study)	RECIST 1.1	1 (100) CR/PR	None
(1/2014, PC)	(mean 1.5 Gbq)		@ 4 mo
Pöpperl et al[45]	SIR-Spheres	Breast (4, data extracted from larger study)	PET	3 (100) Regression	None
(4/2005, PC)	(mean 2.27 Gbq)		@ 3 mo	1 lost

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.